CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Reversibly binds to the 50S subunit of bacterial ribosomes, inhibiting peptide bond formation and protein synthesis. May also act as a bacterial protein synthesis inhibitor by dissociating ribosomes.
| Metabolism | Primarily hepatic via CYP3A4 and possibly other cytochrome P450 enzymes. Metabolites include N-demethylclindamycin and sulfoxide derivatives. |
| Excretion | Clindamycin is primarily excreted via bile and feces (approximately 90% as metabolites), with renal elimination accounting for about 10% (parent drug and N-demethylated metabolite). Less than 1% is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life is approximately 2.4 hours in adults with normal renal function, but increases to 3-5 hours in patients with severe hepatic impairment. Renal impairment has minimal effect. In neonates, half-life may be prolonged (up to 8-12 hours). |
| Protein binding | Clindamycin is 60-95% bound to plasma proteins (primarily albumin). Binding is concentration-dependent and decreases at higher concentrations. |
| Volume of Distribution | The volume of distribution is approximately 0.6-1.2 L/kg (average 0.7 L/kg), indicating extensive tissue penetration. It distributes into most body tissues and fluids, including bone, abscesses, and cerebrospinal fluid (only when meninges are inflamed). |
| Bioavailability | Oral: Approximately 90% (rapidly absorbed; food does not significantly affect absorption). IM: Complete absorption. IV: 100% bioavailable. |
| Onset of Action | Intravenous: Rapid, within minutes after infusion. Intramuscular: 1-2 hours. Oral: 1-2 hours. |
| Duration of Action | Approximately 6-8 hours for IV/IM dosing (every 6-8 hour dosing interval). Oral dosing provides similar duration. Note: For anaerobic infections, longer intervals (every 12 hours) may be used for convenience but efficacy data support every 6-8 hours. |
| Molecular Weight | 504.96 |
Adult: 300-600 mg IV every 6-8 hours, up to 2.7 g/day in 3-4 divided doses for severe infections.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR >30 mL/min; for GFR <30 mL/min, use normal dose but extend interval to every 12-24 hours or consider alternative due to potential toxicity. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: reduce dose by 50-75% and monitor hepatic function. |
| Pediatric use | Children: 10-40 mg/kg/day IV divided every 6-8 hours (max 2.7 g/day); neonates: 15-20 mg/kg/day IV divided every 8-12 hours. |
| Geriatric use | Elderly: no specific dose adjustment required, but monitor renal function and consider reduced clearance due to age-related renal decline. |
| 1st trimester | Safe: No evidence of harm in first trimester based on human data; crosses placenta. |
| 2nd trimester | Safe: Commonly used in second trimester for infections; no known teratogenicity. |
| 3rd trimester | Safe: Used to treat infections in third trimester; risk of pseudomembranous colitis in neonate if used near term. |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Placental transfer | Crosses placenta; fetal serum levels reach 50% of maternal levels. |
| Breastfeeding | Excreted into breast milk in small amounts; unlikely to cause adverse effects in infant. Monitor for diarrhea or rash. |
■ FDA Black Box Warning
Clindamycin can cause severe and sometimes fatal colitis (including pseudomembranous colitis) due to Clostridium difficile overgrowth. Discontinue use if significant diarrhea occurs.
| Common Effects | Diarrhea (including C. difficile) |
| Serious Effects |
Hypersensitivity to clindamycin or lincomycinHistory of pseudomembranous colitisKnown gastrointestinal disease (severe colitis)
| Precautions | Risk of Clostridium difficile-associated diarrhea (CDAD) and pseudomembranous colitis, May cause severe hypersensitivity reactions including anaphylaxis and Stevens-Johnson syndrome, Neuromuscular blocking effects may potentiate other neuromuscular blocking agents, Prolonged use may result in overgrowth of nonsusceptible organisms (superinfection), Renal and hepatic impairment may require dose adjustment |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Clindamycin phosphate is classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, but no adequate and well-controlled studies in pregnant women exist. First trimester: No evidence of teratogenicity; second and third trimesters: considered safe for use. However, use only if clearly needed. |
| Fetal Monitoring | Monitor maternal liver function, renal function, and complete blood count periodically during prolonged therapy. Observe the neonate for potential gastrointestinal disturbances (e.g., diarrhea, colitis). No specific fetal monitoring required. |
| Fertility Effects | No known adverse effects on fertility. Animal studies have not shown impaired fertility. |
| No significant food interactions; may be taken with or without food. However, oral clindamycin should be taken with water to reduce esophageal irritation. Avoid alcohol during therapy and for 3 days after completion due to possible disulfiram-like reaction (case reports, rare). |
| Clinical Pearls | Clindamycin phosphate is a prodrug that is rapidly hydrolyzed to active clindamycin. It exhibits time-dependent killing; optimize dosing interval over peak concentration. In renal impairment, dose adjustment is not required but monitor hepatic function. Avoid rapid intravenous administration to reduce risk of hypotension and cardiac arrhythmias. Consider pseudomembranous colitis risk; stool testing for Clostridium difficile toxin is indicated if diarrhea develops. For anaerobic infections, clindamycin is first-line for lung abscess, aspiration pneumonia, and diabetic foot ulcers. Penetrates bone well; used in osteomyelitis secondary to susceptible anaerobes. Do not use as monotherapy for meningitis due to poor CNS penetration. |
| Patient Advice | Complete the full course of treatment even if you feel better. · Report any severe or persistent diarrhea to your healthcare provider immediately. · This medication may increase sensitivity to sunlight; use sunscreen and protective clothing. · Inform your doctor if you have kidney or liver disease, asthma, or a history of colitis. · Avoid alcohol while on this medication and for 72 hours after the last dose. · Take with a full glass of water to prevent esophageal irritation. |